Report Detail
Global Biosimilar Monoclonal Antibodies Market Growth 2019-2024
- RnM3290204 |
- 09 April, 2019 |
- Global |
- 138 Pages |
- LPI(LP Information) |
- Pharma & Healthcare
Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.
The classification of Biosimilar Monoclonal Antibodies includes Infliximab, Rituximab, Trastuzumab, Adalimumab and Other, and the sales proportion of Infliximab in 2017 is about 36.5%.
Biosimilar Monoclonal Antibodies is widely used for Oncology, Autoimmune Disease and Others. The most proportion of Biosimilar Monoclonal Antibodies is sales in Autoimmune Disease, and the consumption proportion is about 85.6% in 2017.
According to this study, over the next five years the Biosimilar Monoclonal Antibodies market will register a 27.5% CAGR in terms of revenue, the global market size will reach US$ 9240 million by 2024, from US$ 2750 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Biosimilar Monoclonal Antibodies business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Biosimilar Monoclonal Antibodies market by product type, application, key manufacturers and key regions and countries.
This study considers the Biosimilar Monoclonal Antibodies value and volume generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Infliximab
Rituximab
Trastuzumab
Adalimumab
Other
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Oncology
Autoimmune Disease
Other
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Celltrion
Pfizer (Hospira)
3SBIO
Novartis (Sandoz)
Dr Reddy’s
Celgen Biopharma
Cadila Healthcare
Hisun Pharma
Torrent Pharmaceuticals
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Biosimilar Monoclonal Antibodies consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Biosimilar Monoclonal Antibodies market by identifying its various subsegments.
Focuses on the key global Biosimilar Monoclonal Antibodies manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Biosimilar Monoclonal Antibodies with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Biosimilar Monoclonal Antibodies submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Table of Contents
2019-2024 Global Biosimilar Monoclonal Antibodies Consumption Market Report
1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Research Objectives
- 1.3 Years Considered
- 1.4 Market Research Methodology
- 1.5 Economic Indicators
- 1.6 Currency Considered
2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Biosimilar Monoclonal Antibodies Consumption 2014-2024
- 2.1.2 Biosimilar Monoclonal Antibodies Consumption CAGR by Region
- 2.2 Biosimilar Monoclonal Antibodies Segment by Type
- 2.2.1 Infliximab
- 2.2.2 Rituximab
- 2.2.3 Trastuzumab
- 2.2.4 Adalimumab
- 2.2.5 Other
- 2.3 Biosimilar Monoclonal Antibodies Consumption by Type
- 2.3.1 Global Biosimilar Monoclonal Antibodies Consumption Market Share by Type (2014-2019)
- 2.3.2 Global Biosimilar Monoclonal Antibodies Revenue and Market Share by Type (2014-2019)
- 2.3.3 Global Biosimilar Monoclonal Antibodies Sale Price by Type (2014-2019)
- 2.4 Biosimilar Monoclonal Antibodies Segment by Application
- 2.4.1 Oncology
- 2.4.2 Autoimmune Disease
- 2.4.3 Other
- 2.5 Biosimilar Monoclonal Antibodies Consumption by Application
- 2.5.1 Global Biosimilar Monoclonal Antibodies Consumption Market Share by Application (2014-2019)
- 2.5.2 Global Biosimilar Monoclonal Antibodies Value and Market Share by Application (2014-2019)
- 2.5.3 Global Biosimilar Monoclonal Antibodies Sale Price by Application (2014-2019)
3 Global Biosimilar Monoclonal Antibodies by Players
- 3.1 Global Biosimilar Monoclonal Antibodies Sales Market Share by Players
- 3.1.1 Global Biosimilar Monoclonal Antibodies Sales by Players (2017-2019)
- 3.1.2 Global Biosimilar Monoclonal Antibodies Sales Market Share by Players (2017-2019)
- 3.2 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Players
- 3.2.1 Global Biosimilar Monoclonal Antibodies Revenue by Players (2017-2019)
- 3.2.2 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Players (2017-2019)
- 3.3 Global Biosimilar Monoclonal Antibodies Sale Price by Players
- 3.4 Global Biosimilar Monoclonal Antibodies Manufacturing Base Distribution, Sales Area, Product Types by Players
- 3.4.1 Global Biosimilar Monoclonal Antibodies Manufacturing Base Distribution and Sales Area by Players
- 3.4.2 Players Biosimilar Monoclonal Antibodies Products Offered
- 3.5 Market Concentration Rate Analysis
- 3.5.1 Competition Landscape Analysis
- 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion
4 Biosimilar Monoclonal Antibodies by Regions
- 4.1 Biosimilar Monoclonal Antibodies by Regions
- 4.1.1 Global Biosimilar Monoclonal Antibodies Consumption by Regions
- 4.1.2 Global Biosimilar Monoclonal Antibodies Value by Regions
- 4.2 Americas Biosimilar Monoclonal Antibodies Consumption Growth
- 4.3 APAC Biosimilar Monoclonal Antibodies Consumption Growth
- 4.4 Europe Biosimilar Monoclonal Antibodies Consumption Growth
- 4.5 Middle East & Africa Biosimilar Monoclonal Antibodies Consumption Growth
5 Americas
- 5.1 Americas Biosimilar Monoclonal Antibodies Consumption by Countries
- 5.1.1 Americas Biosimilar Monoclonal Antibodies Consumption by Countries (2014-2019)
- 5.1.2 Americas Biosimilar Monoclonal Antibodies Value by Countries (2014-2019)
- 5.2 Americas Biosimilar Monoclonal Antibodies Consumption by Type
- 5.3 Americas Biosimilar Monoclonal Antibodies Consumption by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Key Economic Indicators of Few Americas Countries
6 APAC
- 6.1 APAC Biosimilar Monoclonal Antibodies Consumption by Countries
- 6.1.1 APAC Biosimilar Monoclonal Antibodies Consumption by Countries (2014-2019)
- 6.1.2 APAC Biosimilar Monoclonal Antibodies Value by Countries (2014-2019)
- 6.2 APAC Biosimilar Monoclonal Antibodies Consumption by Type
- 6.3 APAC Biosimilar Monoclonal Antibodies Consumption by Application
- 6.4 China
- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 Key Economic Indicators of Few APAC Countries
7 Europe
- 7.1 Europe Biosimilar Monoclonal Antibodies by Countries
- 7.1.1 Europe Biosimilar Monoclonal Antibodies Consumption by Countries (2014-2019)
- 7.1.2 Europe Biosimilar Monoclonal Antibodies Value by Countries (2014-2019)
- 7.2 Europe Biosimilar Monoclonal Antibodies Consumption by Type
- 7.3 Europe Biosimilar Monoclonal Antibodies Consumption by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
- 7.9 Spain
- 7.10 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
- 8.1 Middle East & Africa Biosimilar Monoclonal Antibodies by Countries
- 8.1.1 Middle East & Africa Biosimilar Monoclonal Antibodies Consumption by Countries (2014-2019)
- 8.1.2 Middle East & Africa Biosimilar Monoclonal Antibodies Value by Countries (2014-2019)
- 8.2 Middle East & Africa Biosimilar Monoclonal Antibodies Consumption by Type
- 8.3 Middle East & Africa Biosimilar Monoclonal Antibodies Consumption by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers and Impact
- 9.1.1 Growing Demand from Key Regions
- 9.1.2 Growing Demand from Key Applications and Potential Industries
- 9.2 Market Challenges and Impact
- 9.3 Market Trends
10 Marketing, Distributors and Customer
- 10.1 Sales Channel
- 10.1.1 Direct Channels
- 10.1.2 Indirect Channels
- 10.2 Biosimilar Monoclonal Antibodies Distributors
- 10.3 Biosimilar Monoclonal Antibodies Customer
11 Global Biosimilar Monoclonal Antibodies Market Forecast
- 11.1 Global Biosimilar Monoclonal Antibodies Consumption Forecast (2019-2024)
- 11.2 Global Biosimilar Monoclonal Antibodies Forecast by Regions
- 11.2.1 Global Biosimilar Monoclonal Antibodies Forecast by Regions (2019-2024)
- 11.2.2 Global Biosimilar Monoclonal Antibodies Value Forecast by Regions (2019-2024)
- 11.2.3 Americas Consumption Forecast
- 11.2.4 APAC Consumption Forecast
- 11.2.5 Europe Consumption Forecast
- 11.2.6 Middle East & Africa Consumption Forecast
- 11.3 Americas Forecast by Countries
- 11.3.1 United States Market Forecast
- 11.3.2 Canada Market Forecast
- 11.3.3 Mexico Market Forecast
- 11.3.4 Brazil Market Forecast
- 11.4 APAC Forecast by Countries
- 11.4.1 China Market Forecast
- 11.4.2 Japan Market Forecast
- 11.4.3 Korea Market Forecast
- 11.4.4 Southeast Asia Market Forecast
- 11.4.5 India Market Forecast
- 11.4.6 Australia Market Forecast
- 11.5 Europe Forecast by Countries
- 11.5.1 Germany Market Forecast
- 11.5.2 France Market Forecast
- 11.5.3 UK Market Forecast
- 11.5.4 Italy Market Forecast
- 11.5.5 Russia Market Forecast
- 11.5.6 Spain Market Forecast
- 11.6 Middle East & Africa Forecast by Countries
- 11.6.1 Egypt Market Forecast
- 11.6.2 South Africa Market Forecast
- 11.6.3 Israel Market Forecast
- 11.6.4 Turkey Market Forecast
- 11.6.5 GCC Countries Market Forecast
- 11.7 Global Biosimilar Monoclonal Antibodies Forecast by Type
- 11.8 Global Biosimilar Monoclonal Antibodies Forecast by Application
12 Key Players Analysis
- 12.1 Celltrion
- 12.1.1 Company Details
- 12.1.2 Biosimilar Monoclonal Antibodies Product Offered
- 12.1.3 Celltrion Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.1.4 Main Business Overview
- 12.1.5 Celltrion News
- 12.2 Pfizer (Hospira)
- 12.2.1 Company Details
- 12.2.2 Biosimilar Monoclonal Antibodies Product Offered
- 12.2.3 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.2.4 Main Business Overview
- 12.2.5 Pfizer (Hospira) News
- 12.3 3SBIO
- 12.3.1 Company Details
- 12.3.2 Biosimilar Monoclonal Antibodies Product Offered
- 12.3.3 3SBIO Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.3.4 Main Business Overview
- 12.3.5 3SBIO News
- 12.4 Novartis (Sandoz)
- 12.4.1 Company Details
- 12.4.2 Biosimilar Monoclonal Antibodies Product Offered
- 12.4.3 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.4.4 Main Business Overview
- 12.4.5 Novartis (Sandoz) News
- 12.5 Dr Reddy’s
- 12.5.1 Company Details
- 12.5.2 Biosimilar Monoclonal Antibodies Product Offered
- 12.5.3 Dr Reddy’s Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.5.4 Main Business Overview
- 12.5.5 Dr Reddy’s News
- 12.6 Celgen Biopharma
- 12.6.1 Company Details
- 12.6.2 Biosimilar Monoclonal Antibodies Product Offered
- 12.6.3 Celgen Biopharma Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.6.4 Main Business Overview
- 12.6.5 Celgen Biopharma News
- 12.7 Cadila Healthcare
- 12.7.1 Company Details
- 12.7.2 Biosimilar Monoclonal Antibodies Product Offered
- 12.7.3 Cadila Healthcare Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.7.4 Main Business Overview
- 12.7.5 Cadila Healthcare News
- 12.8 Hisun Pharma
- 12.8.1 Company Details
- 12.8.2 Biosimilar Monoclonal Antibodies Product Offered
- 12.8.3 Hisun Pharma Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.8.4 Main Business Overview
- 12.8.5 Hisun Pharma News
- 12.9 Torrent Pharmaceuticals
- 12.9.1 Company Details
- 12.9.2 Biosimilar Monoclonal Antibodies Product Offered
- 12.9.3 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.9.4 Main Business Overview
- 12.9.5 Torrent Pharmaceuticals News
13 Research Findings and Conclusion
Summary:
Get latest Market Research Reports on Biosimilar Monoclonal Antibodies . Industry analysis & Market Report on Biosimilar Monoclonal Antibodies is a syndicated market report, published as Global Biosimilar Monoclonal Antibodies Market Growth 2019-2024. It is complete Research Study and Industry Analysis of Biosimilar Monoclonal Antibodies market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
